Altamira Therapeutics Files Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
27. Februar 2023 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Altamira’s ability to target different KRAS mutations with a single polyvalent siRNA sequence illustrates versatility and potential of RNA...
Altamira Therapeutics Provides Business Update
27. Januar 2023 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Process for divestiture / partnering of legacy assets continuesStrong data from Bentrio® NASAR study reinforces its therapeutic benefit for...
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
24. Januar 2023 08:17 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Jan. 24, 2023 (GLOBE NEWSWIRE) -- Interim analysis of Australian NASAR trial in seasonal allergic rhinitis shows statistically significant improvement with Bentrio® in nasal...
Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th
10. Januar 2023 08:47 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Company COO Dr. Pañeda will discuss SemaPhoreTM platform’s functionality with mRNA, and:Peptide-based platform for extrahepatic deliveryThe...
Altamira Therapeutics Provides Year-End 2022 Business Update
19. Dezember 2022 08:47 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Dec. 19, 2022 (GLOBE NEWSWIRE) --Altamira Therapeutics Provides Year-End 2022 Business Update Strategic BentrioTM partnering or divestiture process enters decisive phasePartnering...
Altamira Therapeutics Provides Business Update and First Half 2022 Financial Results
30. November 2022 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Nov. 30, 2022 (GLOBE NEWSWIRE) -- BentrioTM nasal spray launched in Hong Kong by partner Nuance Pharma to help protect against viruses and allergensCOVAMID trial with Bentrio in...
Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma
30. November 2022 08:07 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Initiative is Nuance’s first step in penetrating Chinese market with BentrioTMDensely populated Hong Kong (7.3 million) remains negatively...
Altamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid Event
10. November 2022 08:47 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Nov. 10, 2022 (GLOBE NEWSWIRE) -- • TIDES Europe Event will be held on November 16-18, 2022, in Vienna, Austria• Company Chief Development Officer, Covadonga Pañeda, Ph.D., to...
Altamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid Requirement
09. November 2022 08:47 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs today...
Data Published in Peer-Reviewed Journal Demonstrate Protective Effects of Altamira’s Bentrio under Controlled Grass Pollen Exposure
08. November 2022 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Nov. 08, 2022 (GLOBE NEWSWIRE) -- • Publication in International Archives of Allergy and Immunology shows rapid onset and long duration of Bentrio’s protective effects in allergic...